Literature DB >> 19000546

Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting--a case report and review of the literature.

M Woznowski1, I Quack, J Stegbauer, N Büchner, L C Rump, G Schieren.   

Abstract

An appropriate phosphate homeostasis is absolutely required for correct bone mineralization and remodeling, for diverse signaling pathways as well as cell membrane formation. Its disequilibrium results in serious complications like hypophosphatemia and excessively reduced fractional tubule phosphate reabsorption (TRP). A rare cause of such a disturbed phosphate balance is tumor-induced osteomalacia (TIO)--a phosphate wasting disorder sometimes associated with certain mesenchymal tumors. These primitive tumors secrete so-called phosphatonins--recently identified factors involved in the regulation of phosphate homeostasis such as the secreted frizzled related protein 4 (sFRP-4), the fibroblast growth factors 7 and 23 (FGF-7/-23), or the matrix extracellular phosphoglycoprotein (MEPE). Progressive muscular weakness and spontaneous bone fractures caused by inadequate osteoid mineralization are the characteristic clinical symptoms, which completely resolve after tumor resection. Here we report a new case of TIO caused by tumor secreted FGF-23 and review the literature to facilitate the correct diagnosis of this rare disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000546     DOI: 10.5414/cnp70431

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  [An unusual cause of apparent oligoarthritis. A step back and a second look].

Authors:  C Fiehn; C Goerke
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

3.  Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.